Table 3.
Odds ratios (95% CI) for EOC for doubling of androgen concentrations and stratified by grade at diagnosis overall and for serous tumors: the Ovarian Cancer Cohort Consortium (OC3) 1
| Sets | OR (95%CI) | |
|---|---|---|
| Testosterone | ||
|
| ||
| Low grade | 55 | 1.28 (0.80 – 2.07) |
| High grade | ||
| All | 407 | 0.94 (0.79 – 1.12) |
| Serous | 260 | 0.84 (0.67 – 1.04) |
| phet2 | 0.25 | |
| phet3 | 0.12 | |
|
| ||
| Free Testosterone | ||
|
| ||
| Low grade | 38 | 1.34 (0.79 – 2.27) |
| High grade | ||
| All | 277 | 0.95 (0.80 – 1.13) |
| Serous | 180 | 0.92 (0.74 – 1.13) |
| phet2 | 0.24 | |
| phet3 | 0.19 | |
|
| ||
| Androstenedione | ||
|
| ||
| Low grade | 55 | 1.41 (0.86 – 2.31) |
| High grade | ||
| All | 406 | 0.84 (0.69 – 1.01) |
| Serous | 259 | 0.76 (0.60 – 0.96) |
| phet2 | 0.05 | |
| phet3 | 0.02 | |
|
| ||
| DHEAS | ||
|
| ||
| Low grade | 49 | 1.32 (0.89 – 1.97) |
| High grade | ||
| All | 374 | 0.93 (0.81 – 1.07) |
| Serous | 234 | 0.91 (0.76 – 1.08) |
| phet2 | 0.07 | |
| phet3 | 0.06 | |
|
| ||
| SHBG | ||
|
| ||
| Low grade | 38 | 0.59 (0.33 – 1.03) |
| High grade | ||
| All | 286 | 1.12 (0.93 – 1.36) |
| Serous | 185 | 1.17 (0.92 – 1.49) |
| phet2 | 0.02 | |
| phet3 | 0.02 | |
1
Results were derived from conditional logistic regression models, additionally adjusted for OC use (never/ever/missing) and parity (never/ever/missing). Pair-wise heterogeneity tests were performed, using the likelihood ratio test comparing models assuming (1) the same association between exposure and outcomes compared to (2) a model assuming different associations for each subtype.
2
Comparing all high grade subtypes to low grade.
3
Comparing high grade serous to all low grade. DHEAS=dehydroepiandrosterone sulfate; SHBG=sex hormone binding globulin